Imaging

Dr. Annette Von Drygalski
MD, PharmD

Annette von Drygalski, MD, PharmD, is an Associate Clinical Professor of Medicine in the Division of Hematology/Oncology, and Director of the Hemophilia and Thrombosis Treatment Center, Department of Medicine, at the University of California, San Diego. She is also an Adjunct Associate Professor, Department of Molecular and Experimental Medicine at The Scripps Research Institute, La Jolla, California.

Dr. von Drygalski earned her pharmaceutical degree from the Ludwig Maximilians University, and her medical degree from Friedrich Alexander University Erlangen/Nürnberg and Ludwig Maximilians University in Munich, Germany. She completed residency in Internal Medicine at the Medical College of Wisconsin, Milwaukee, and fellowship in Hematology and Oncology at the University of California, San Diego and The Scripps Research Institute.

Dr. von Drygalski is board certified in hematology, oncology, and internal medicine. She is a member of the American Society of Hematology, the World Federation of Hemophilia and the Hemostasis and Thrombosis Research Society.

Dr. von Drygalski is dedicated to the care of patients with hemophilia and other bleeding disorders. In this role, Dr. von Drygalski developed basic, translational and clinical research interests addressing the evolving needs of aging patients with hemophilia, such as cardiovascular and joint disease. 

Key Publications

E Martin, RFW Barnes, CM Moran, S Holle, TH Hughes, RE Moore, A von Drygalski. Efficacy and safety of point-of-care ultrasound-guided intra-articular corticosteroid joint injections in patients with hemophilic arthropathy. Haemophilia. 2016 Aug 3. doi: 10.1111/hae.13057. [Epub ahead of print]

W Kidder, EY Chang, C Moran, S Rose, and A von Drygalski.   Propagation of Hemophilic Arthropathy - the Role of Abnormal Angiogenesis and Vascular Remodeling for Recurrent Joint Bleeding. Microcirculation. 2016 Jul;23(5):373-8. doi: 10.1111/micc.12273

V Bhat, M Olmer, S Joshi, DL Durden, T Cramer, R Barnes, ST Ball, TH Hughes, M Silva, LV Luck, R Moore, LO Mosnier, A von Drygalski. Vascular Remodeling Underlies Re-bleeding In Hemophilic Arthropathy. Am J Hematol. 2015 Nov;90(11):1027-35. doi: 10.1002/ajh.24133. Epub 2015 Oct 8.

W Kidder, S Ngugen, J Larios, J Bergstrom, A Ceponis, A von Drygalski. Point-of-care musculoskeletal ultrasound is critical for the diagnosis of hemarthroses, inflammation and soft tissue abnormalities in adult patients with painful hemophilic arthropathy. Haemophilia. 2015 Jul;21(4):530-7.

A Ceponis, I Wong-Sefidan, CS Glass, A von Drygalski.Rapid musculoskeletal ultrasound for painful episodes in adult hemophilia patients. Haemophilia 2013;19:790-798 [Epub 2013 May 15]

Current Positions/Chairs:

  • Director
    Hemophilia and Thrombosis Treatment Center

Key Institutions

  • University of California San Diego
    Hemophilia and Thrombosis Treatment Center, Department of Medicine
    USA

Research Interests

  • Pathobiology of hemophilic joint disease, and impact of vascular remodeling on re-bleeding, perpetuated bleeding, target joint development and progression of hemophilic arthropathy
  • Utility of point-of-care musculoskeletal ultrasound for rapid bleed detection and the management of hemophilic arthropathy
  • Etiology of hypertension in hemophilia and relation to hemophilic arthropathy
  • “FVa activity augmentation” for the development of novel bypassing strategies in patients with inhibitors, bleeding with novel oral anti-coagulants and traumatic bleeding

Achievements

  • Discovery that vascular remodeling is associated with joint bleeding, is unique to hemophilia and not present in other arthritic conditions, and probably predisposes to recurrent bleeds
  • Patient perception and physician judgement are unreliable to determine if pains are associated with bleeding in hemophilia as ascertained my objective imaging with musculoskeletal ultrasound
  • Introduction of point-of-care musculoskeletal ultrasound into hemophilia treatment centers to assist with diagnosis of pains and management of hemophilic arthropathy
  • Discovery that the prevalence of hypertension is significantly higher in patients with hemophilia compared to the general population
  • Development of superFVa , a variant of FV that is resistant against inactivation by Activated Protein C and stabilized via disulfide bonds